US Patent

US11331325 — Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same

Method of Use · Assigned to Clarus Therapeutics Inc · Expires 2027-01-06 · 1y remaining

Vulnerability score 88/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a drug delivery system for oral administration of hydrophobic drugs, including formulations of testosterone and testosterone esters.

USPTO Abstract

A drug delivery system for oral administration of hydrophobic drugs with enhanced and extended absorption and improved pharmacokinetics is provided. In one embodiment, formulations comprising testosterone and testosterone esters, e.g., testosterone palmitate, are disclosed. Methods of treating a hormone deficiency or effecting male contraception with the inventive formulations are also provided.

Drugs covered by this patent

Aveed (TESTOSTERONE UNDECANOATE) · Marius

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2506`	—	Aveed
`U-2506`	—	Aveed
`U-2506`	—	Aveed

Patent Metadata

Patent number: US11331325
Jurisdiction: US
Classification: Method of Use
Expires: 2027-01-06
Drug substance claim: No
Drug product claim: No
Assignee: Clarus Therapeutics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.